Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Target Recruit Count
- 61
- Registration Number
- NCT00085462
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸NCI - Surgery Branch, Bethesda, Maryland, United States
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
- Conditions
- Central Nervous System TumorBrain Tumor
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: etoposideRadiation: radiation therapy
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00085098
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Driscoll Children's Hospital, Corpus Christi, Texas, United States
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
- Conditions
- Central Nervous System Tumor, Pediatric
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapyDrug: Dactinomycin
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00084838
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
- Conditions
- LymphomaFanconi AnemiaMyelodysplastic SyndromesSarcomaLeukemiaChildhood Langerhans Cell HistiocytosisNeuroblastomaUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- Biological: anti-thymocyte globulinDrug: cyclophosphamideDrug: busulfanRadiation: radiation therapyDrug: melphalanDrug: fludarabine phosphateDrug: methylprednisolone
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00084695
- Locations
- 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: vincristine sulfateRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00002676
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Target Recruit Count
- 230
- Registration Number
- NCT00003859
- Locations
- 🇬🇧
St. James's Hospital, Leeds, England, United Kingdom
Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 20
- Registration Number
- NCT00002905
- Locations
- 🇮🇹
Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Bone Marrow Transplantation in Treating Patients With Leukemia
- Conditions
- LeukemiaGraft Versus Host DiseaseLymphoma
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00006451
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
- Conditions
- Breast Cancer
- Interventions
- Biological: trastuzumabDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: paclitaxelDrug: tamoxifen citrate
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 200
- Registration Number
- NCT00003992
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- PainProstate Cancer
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005960
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Associates of Hematology/Oncology, Upland, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.